#United States #New York #Pomerantz LLP #Valneva SE #IXCHIQ

Pomerantz Law Firm Takes Action on Behalf of Valneva Investors

Pomerantz LLP, a leading law firm, has initiated an investigation into potential securities fraud involving Valneva SE, a biotechnology company known for developing vaccines, particularly its chikungunya virus vaccine, IXCHIQ. The law firm is reaching out to investors who may have suffered losses due to the company's recent controversies.

In a recent notice, the U.S. Centers for Disease Control and Prevention (CDC) announced it is looking into reports of cardiac and neurological issues among individuals aged 65 and older who received the IXCHIQ vaccine. This alarming news, released on February 25, 2025, raised significant concerns about the vaccine's safety and quickly caught the attention of investors and the media alike.

Following the CDC's announcement, the value of Valneva's American Depositary Receipt (ADR) experienced a notable drop, falling by $1.06 per share or approximately 13.57% over four trading sessions. The stock closed at $6.75 on February 28, 2025, underscoring the deepening anxiety among investors and raising questions about the company's governance and transparency.

Pomerantz LLP is particularly focused on whether Valneva, along with its executives and directors, may have participated in unlawful business practices or securities fraud that misled investors regarding the safety and efficacy of its vaccine. The law firm, known for its extensive experience in corporate, securities, and antitrust class action litigation, aims to protect the rights of the investor community who feel wronged by potential misconduct.

With a legacy spanning over 85 years, Pomerantz has a proven track record of achieving substantial settlements and jury awards for clients in similar cases. The firm recognizes that the victims of securities fraud deserve justice and is committed to investigating the circumstances surrounding Valneva's situation.

Investors who wish to join the investigation or have claims can reach out directly to Pomerantz LLP. Danielle Peyton, a representative of the firm, can be contacted via email or by phone, and she urges those affected to come forward to ensure that their voices are heard in the legal proceedings.

The situation is still evolving, and with ongoing CDC investigations, the implications for Valneva SE and its investors will unfold in due time. Considering the potential ramifications of such investigations, investors are encouraged to stay informed about future developments and their rights regarding potential claims for damages resulting from the company's actions.

In essence, the Pomerantz investigation serves as a crucial reminder of the importance of corporate accountability in the biotechnology sector, particularly as it relates to health and safety issues. As the situation develops, it highlights the need for continuous scrutiny of companies like Valneva that play a vital role in public health through their vaccine initiatives.